Section Arrow
LBRX.NASDAQ
- LB Pharmaceuticals Inc
Quotes are at least 15-min delayed:2025/09/13 12:10 EDT
Regular Hours
Last
 16.8
-0.5 (-2.89%)
Day High 
18.21 
Prev. Close
17.3 
1-M High
20.25 
Volume 
458.09K 
Bid
16.47
Ask
16.8
Day Low
15.7942 
Open
17.6 
1-M Low
16.5 
Market Cap 
347.73M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA -- 
20-SMA -- 
50-SMA -- 
52-W High 20.25 
52-W Low 15.7942 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.46/--
Enterprise Value
350.95M
Balance Sheet
Book Value Per Share
N/A
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
--
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
COCPCocrystal Pharma1.58+0.14+9.72%-- 
ADAPAdaptimmune Therapeutics plc0.056+0.0055+10.89%-- 
PLRZPolyrizon Ltd1.2+0.2225+22.76%-- 
MRNAModerna23.51-1.88-7.40%-- 
HCWBHCW Biologics Inc5.59+2.27+68.37%-- 
Quotes are at least 15-min delayed:2025/09/13 12:10 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broadtherapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.